Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Treatment-emergent adverse event (TEAEs) occurring at weeks 4, 8 and 12

From: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)

 

Week 4

Week 8

Week 12

Patients n

60

58

53

Patients with ≥ 1 TEAE

1 (1.7%)

2 (3.4%)

3 (5.7%)

•Injection site erythema

1 (1.7%)

1 (1.7%)

1 (1.9%)

•Dizziness

-

1 (1.7%)

-

•Abdominal pain

-

-

1 (1.9%)

•Neck pain and somnolence

-

-

1 (1.0%)

Discontinuation due to TEAEs

-

-

-

Discontinuation due to ineffectiveness

-

-

-

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us